Bristol Myers (BMY) announces 1st data from Zenbexus with Daratumumab, Phase 3 showed a statistically significant and ...
In recent months, the Co. removed one of its key land and power partners from the development, the sources say.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results